mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.
Company profile
Ticker
VTRS, 0A5V
Exchange
Website
CEO
Michael Goettler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Upjohn Inc
SEC CIK
Corporate docs
Subsidiaries
Agila Australasia Pty Ltd • Alphapharm Pty. Ltd. • Mylan Australia Holding Pty Ltd • Mylan Australia Pty Limited • Upjohn Australia Pty Ltd • Viatris Pty. Ltd. • Arcana Arzneimittel GmbH • Mylan Österreich GmbH • Viatris GX BV • Viatris BV ...
IRS number
834364296
VTRS stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
9 May 24
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results
28 Feb 24
8-K/A
Entry into a Material Definitive Agreement
30 Jan 24
8-K/A
Departure of Directors or Certain Officers
15 Dec 23
8-K
Departure of Directors or Certain Officers
15 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Robert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders
15 Dec 23
Transcripts
VTRS
Earnings call transcript
2024 Q1
9 May 24
VTRS
Earnings call transcript
2023 Q3
7 Nov 23
VTRS
Earnings call transcript
2023 Q2
7 Aug 23
VTRS
Earnings call transcript
2023 Q2
7 Aug 23
VTRS
Earnings call transcript
2023 Q1
8 May 23
VTRS
Earnings call transcript
2022 Q4
27 Feb 23
VTRS
Earnings call transcript
2022 Q3
7 Nov 22
VTRS
Earnings call transcript
2022 Q2
8 Aug 22
VTRS
Earnings call transcript
2022 Q1
9 May 22
VTRS
Earnings call transcript
2021 Q4
28 Feb 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
57.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 809 |
Opened positions | 107 |
Closed positions | 223 |
Increased positions | 211 |
Reduced positions | 341 |
13F shares | Current |
---|---|
Total value | 6.47 tn |
Total shares | 683.92 mm |
Total puts | 1.08 mm |
Total calls | 2.24 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 142.26 mm | $1.54 tn |
Davis Selected Advisers | 62.66 mm | $678.63 bn |
STT State Street | 61.92 mm | $670.64 bn |
T. Rowe Price | 49.47 mm | $535.72 mm |
IVZ Invesco | 30.14 mm | $326.45 bn |
Pacer Advisors | 20.85 mm | $225.84 bn |
Camber Capital Management | 18.50 mm | $200.36 mm |
Slate Path Capital | 15.24 mm | $165.01 bn |
MS Morgan Stanley | 13.23 mm | $143.32 bn |
Dimensional Fund Advisors | 12.20 mm | $132.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Goff Corinne Le | RSU Common Stock | Grant | Acquire A | No | No | 0 | 110,162 | 0.00 | 110,162 |
18 Apr 24 | Goff Corinne Le | RSU Common Stock | Grant | Acquire A | No | No | 0 | 78,688 | 0.00 | 78,688 |
2 Apr 24 | Rajiv Malik | RSU Common Stock | Grant | Acquire A | No | No | 0 | 18,845 | 0.00 | 18,845 |
13 Mar 24 | Anthony Mauro | Common Stock | Sell | Dispose S | No | No | 12.0948 | 250,000 | 3.02 mm | 243,044 |
4 Mar 24 | Theodora Mistras | RSU Common Stock | Grant | Acquire A | No | No | 0 | 93,447 | 0.00 | 93,447 |
News
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
9 May 24
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
9 May 24
Viatris Q1 2024 GAAP EPS $0.67, Inline, Sales $3.663B Miss $3.691B Estimate
9 May 24
Piper Sandler Reiterates Neutral on Viatris, Raises Price Target to $13
28 Mar 24
Looking Into Viatris's Recent Short Interest
15 Mar 24
Press releases
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
10 May 24
Viatris to Participate in the BofA Securities 2024 Health Care Conference
2 May 24
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
16 Apr 24
Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada
15 Apr 24
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
27 Mar 24